September 16, 2024

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear.

Me gusta

Guardar

Cite This Study

Chan et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5846db6db64358752135c https://doi.org/https://doi.org/10.1056/nejmoa2403991

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) <i>(</i>Alliance A021202<i>)</i>.2019 · 43 citations
2Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours2013 · 120 citations
3The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology1993 · 15,968 citations
4Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study2020 · 190 citations
5Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)2022 · 295 citations

Me gusta

Guardar